| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,965,931 ) |
| | 2025 | 2025 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44CA298512 | Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma | 000 | 1 | NIH | 12/24/2024 | $1,024,967 |
| | 2025 | 2025 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R42AI132047 | A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome | 000 | 5 | NIH | 3/11/2025 | $955,865 |
| | 2025 | 2024 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44NS132666 | Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS) | 001 | 2 | NIH | 12/4/2024 | $40,095 |
| | 2025 | 2024 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI157074 | Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas | 000 | 3 | NIH | 11/18/2024 | $0 |
| | 2025 | 2023 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44NS132666 | Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS) | 000 | 1 | NIH | 12/4/2024 | -$40,095 |
| | 2025 | 2023 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44CA265424 | Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas | 000 | 3 | NIH | 10/29/2024 | $0 |
| | 2025 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43HL162238 | Development of a broad spectrum antimicrobial to combat chronic lung infection | 000 | 1 | NIH | 1/3/2025 | -$14,901 |
| | 2025 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44DK135154 | Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes | 000 | 1 | NIH | 2/12/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $4,075,188 ) |
| | 2024 | 2024 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R25AG078135 | Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF) | 000 | 3 | NIH | 8/8/2024 | $162,000 |
| | 2024 | 2024 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44DK135154 | Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes | 000 | 3 | NIH | 7/31/2024 | $999,828 |
| | 2024 | 2024 | CELDARA MEDICAL | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R42AI132047 | A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome | 000 | 4 | NIH | 2/22/2024 | $993,938 |
| | 2024 | 2024 | CELDARA MEDICAL | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI157074 | Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas | 000 | 3 | NIH | 5/16/2024 | $998,375 |
| | 2024 | 2024 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44NS132666 | Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS) | 000 | 2 | NIH | 8/30/2024 | $921,486 |
| | 2024 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43CA271880 | CAR T platform to treat solid tumors | 000 | 1 | NIH | 4/26/2024 | $0 |
| | 2024 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R41AI157527 | A Novel Broad-spectrum Antiviral Agent | 000 | 2 | NIH | 11/15/2023 | $0 |
| | 2024 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI157074 | Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas | 001 | 1 | NIH | 7/25/2024 | $0 |
| | 2024 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI136273 | Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus | 000 | 5 | NIH | 8/28/2024 | $0 |
| | 2024 | 2021 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44DK117714 | Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM | 000 | 3 | NIH | 2/13/2024 | $0 |
| | 2024 | 2020 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | UT2GM130176 | DRIVEN: Accelerating Medical Entrepreneurship in the Northeast | 000 | 3 | NIH | 10/13/2023 | -$439 |
| | 2024 | 2020 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT STE 240 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43AI142911 | A novel antibody therapy for Sin Nombre virus infection | 000 | 2 | NIH | 11/14/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $4,652,299 ) |
| | 2023 | 2023 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R42AI132047 | A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome | 000 | 3 | NIH | 3/1/2023 | $1,000,000 |
| | 2023 | 2023 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R25AG078135 | Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF) | 000 | 2 | NIH | 6/14/2023 | $162,000 |
| | 2023 | 2023 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44CA265424 | Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas | 000 | 3 | NIH | 8/9/2023 | $769,404 |
| | 2023 | 2023 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44DK135154 | Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes | 003 | 2 | NIH | 9/8/2023 | $999,432 |
| | 2023 | 2023 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI157074 | Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas | 000 | 2 | NIH | 6/12/2023 | $999,635 |
| | 2023 | 2023 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44NS132666 | Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS) | 000 | 1 | NIH | 9/18/2023 | $466,950 |
| | 2023 | 2023 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43NS127620 | Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke | 000 | 1 | NIH | 9/19/2023 | $231,974 |
| | 2023 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44DK135154 | Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes | 002 | 1 | NIH | 2/8/2023 | $0 |
| | 2023 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44DK135154 | Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes | 001 | 1 | NIH | 1/18/2023 | $32,078 |
| | 2023 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44DK135154 | Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes | 000 | 1 | NIH | 10/21/2022 | $0 |
| | 2023 | 2020 | CELDARA MEDICAL | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AR073067 | Cellular Immunotherapy for Systemic Sclerosis | 000 | 3 | NIH | 4/6/2023 | $0 |
| | 2023 | 2020 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | UT2GM130176 | DRIVEN: Accelerating Medical Entrepreneurship in the Northeast | 000 | 3 | NIH | 8/18/2023 | $0 |
| | 2023 | 2019 | CELDARA MEDICAL | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AR072170 | Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma | 000 | 3 | NIH | 2/2/2023 | -$9,174 |
|
| Issue Date FY: 2022 ( Subtotal = $3,385,441 ) (Continued on the next page) |
| | 2022 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI136273 | Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus | 000 | 5 | NIH | 2/14/2022 | $974,351 |
| | 2022 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44DK135154 | Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes | 000 | 1 | NIH | 9/22/2022 | $267,818 |
| | 2022 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44CA265424 | Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas | 001 | 2 | NIH | 9/1/2022 | $712,718 |
| | 2022 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43CA271880 | CAR T platform to treat solid tumors | 000 | 1 | NIH | 7/25/2022 | $368,052 |
| | 2022 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R25AG078135 | Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF) | 000 | 1 | NIH | 8/1/2022 | $162,000 |
| | 2022 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R41AI157527 | A Novel Broad-spectrum Antiviral Agent | 000 | 2 | NIH | 12/9/2021 | $290,738 |
| | 2022 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI157074 | Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas | 000 | 1 | NIH | 4/25/2022 | $300,000 |
| | 2022 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI136273 | Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus | 001 | 5 | NIH | 7/25/2022 | $0 |
| | 2022 | 2022 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43HL162238 | Development of a broad spectrum antimicrobial to combat chronic lung infection | 000 | 1 | NIH | 8/9/2022 | $300,590 |
| | 2022 | 2021 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44CA265424 | Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas | 000 | 1 | NIH | 8/29/2022 | $0 |
| | 2022 | 2021 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44DK117714 | Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM | 000 | 3 | NIH | 9/8/2022 | $0 |
| | 2022 | 2020 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R41AI147902 | Autonomous RNA-Mediated Anti-Influenza A Virus Therapeutics (AMRed Therapeutics) | 000 | 1 | NIH | 8/16/2022 | $0 |
| | 2022 | 2020 | CELDARA MEDICAL, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43DK125161 | Biomarker of IAPP dysfunction in prediabetes and early type 2 diabetes mellitus (T2DM) | 000 | 1 | NIH | 6/7/2022 | $0 |
|
